Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant : a cost-effectiveness analysis in Scotland

Parker, Christopher, Woods, Bethan Sarah orcid.org/0000-0002-7669-9415, Eaton, James et al. (7 more authors) (2020) Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant : a cost-effectiveness analysis in Scotland. Journal of Medical Economics. pp. 8-18. ISSN 941-837X

Abstract

Metadata

Authors/Creators:
  • Parker, Christopher
  • Woods, Bethan Sarah ORCID logo https://orcid.org/0000-0002-7669-9415
  • Eaton, James
  • Ma, Esprit
  • Selby, Ross
  • Benson, Eugene
  • Engstrom, Andreas
  • Sajosi, Peter
  • Briggs, Andrew
  • Bonthapally, Vijayveer
Copyright, Publisher and Additional Information: This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details
Keywords: Decision analysis, Health technology assessment, Health utility, Orphan medicine, Quality-adjusted life year
Dates:
  • Accepted: 29 July 2016
  • Published (online): 11 August 2016
  • Published: 2020
Institution: The University of York
Academic Units: The University of York > Faculty of Social Sciences (York) > Centre for Health Economics (York)
Depositing User: Pure (York)
Date Deposited: 21 Mar 2017 17:40
Last Modified: 06 Dec 2023 11:36
Published Version: https://doi.org/10.1080/13696998.2016.1219358
Status: Published
Refereed: Yes
Identification Number: https://doi.org/10.1080/13696998.2016.1219358
Related URLs:

Download

Filename: Parker_Brentuximab_vedotin_cost_effectiveness_HL_manuscript_14_July_2016.doc

Description: Parker_Brentuximab_vedotin_cost_effectiveness_HL_manuscript_14_July_2016

Export

Statistics